This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Feasibility Study of Phototherapy System to Treat H Pylori

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2006 by LumeRx.
Recruitment status was:  Recruiting
Information provided by:
LumeRx Identifier:
First received: March 21, 2006
Last updated: September 19, 2006
Last verified: September 2006
This purpose of this study is to determine whether phototherapy can be used to safely and effectively treat H pylori.

Condition Intervention
Helicobacter Pylori Device: Phototherapy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Phototherapy System to Treat H Pylori

Resource links provided by NLM:

Further study details as provided by LumeRx:

Primary Outcome Measures:
  • Negative urease breath test at five weeks post procedure

Secondary Outcome Measures:
  • Procedural Side Effects
  • Negative urease breath test at 5 days post procedure
  • Reduction in acute post treatment bacterial population with respect to pretreatment samples

Estimated Enrollment: 60
Study Start Date: March 2006
Estimated Study Completion Date: March 2007
Detailed Description:

H pylori causes almost all peptic ulcers and many gastric cancers and is widely prevalent worldwide. Treatment by multiple antibiotics and proton pump inhibitors is effective but are compromised today by significant non compliance due to side effects and duration of required treatment. Also, the increase in antibiotic resistance coupled with the decreased availability of new antibiotics project a significant population of patients who will not be treatable with antibiotics.

A special, visible-light based phototherapy system has been demonstrated to significantly decrease the viability of H pylori in vitro and in a brief clinical experiment.

This study will evaluate the safety and short term efficacy in up to 60 patients of the phototherapy system to treat H pylori.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age > 18 and < 90
  • Documented positive for H. pylori infection by urease breath test, stool antigen or histology within thirty days prior to procedure
  • Willing to comply with study requirements
  • Able to undergo endoscopic esophagogastroduodenoscopy (EGD) with biopsy

Exclusion Criteria:

  • History of gastric or duodenal carcinoma
  • History of prior gastric or duodenal surgery
  • Oral or intravenous antibiotics use within previous one month
  • Use of bismuth subsalicylate (Pepto Bismol) within previous one month
  • Use of photosensitizing drugs or nutritional supplements within previous one month
  • Active peptic ulcer disease (gastric or duodenal ulcer)
  • Esophagitis Grade II or higher
  • Oral or intravenous antibiotics use within previous one month
  • History of a bleeding disorder or anti-coagulant use that would prevent biopsy
  • PPI treatment two weeks prior to the scheduled endoscopy
  • Positive Pregnancy Test
  • Known porphyria
  • Suffer from phenylketonuria (PKU)
  • Signs of jaundice
  • Weight < 100 lb or > 250 lb
  • Previously enrolled in this study
  • Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of this study
  • The subject is inappropriate for study participation, as determined by the Investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00306280

United States, Massachusetts
Beth Israel Deaconness Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Anthony Lembo, MD    617-667-2138   
Contact: Eoin Kelly, BS    (617) 632 1108   
Principal Investigator: Anthony Lembo         
Sub-Investigator: Sinil Sheth         
UMass Memorial Medical Center Recruiting
Worcester, Massachusetts, United States, 01655
Contact: David Cave    508-856-8399   
Contact: Ann Foley    (508) 334-4098   
Principal Investigator: David Cave         
United States, Minnesota
Abbott Northwestern Hospital Not yet recruiting
Minneapolis, Minnesota, United States, 55430
Contact: Robert Ganz, MD    612-871-1145 ext 82941   
Contact: Anne Hopper, BS    (612) 870 5594   
Principal Investigator: Robert Ganz         
Sponsors and Collaborators
  More Information Identifier: NCT00306280     History of Changes
Other Study ID Numbers: lmrx01
Study First Received: March 21, 2006
Last Updated: September 19, 2006

Keywords provided by LumeRx:
Helicobacter pylori
peptic ulcer
gastric cancer processed this record on August 22, 2017